Hepatitis C: Shorter Course Possible with Sofosbuvir; ABT-450/r Combo Seen Effective — Physician’s First Watch
Hepatitis C: Shorter Course Possible with Sofosbuvir; ABT-450/r Combo Seen Effective
By Joe Elia
Sofosbuvir therapy for hepatitis C, criticized for its cost, could be shortened from 12 weeks to 8, according to a randomized, phase III study presented at the International Liver Congress and published in the New England Journal of Medicine. In other phase III studies in NEJM, a combination of drugs was effective both in previously treated as well as untreated patients with hepatitis C. The studies were conducted by the drug makers.
In the sofosbuvir study, an 8-week course including ledipasvir was not inferior to a 12-week course, or to an 8-week course that also added ribavirin. All regimens showed a sustained virologic response rate of roughly 95% at 12 weeks after the completion of therapy.
Another research group studied the combination of a protease inhibitor (ABT-450) and a drug that delays its degradation (ritonavir), plus two inhibitors of hepatitis C virus replication (ombitasvir and dasabuvir). By 12 weeks after treatment completion, combination therapy had produced a sustained virologic response rate of roughly 95% both in patients previously treated with other drugs and in those previously untreated.